These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 36930112)
1. Comprehensive analysis of pan-cancer reveals the potential of SLC16A1 as a prognostic and immunological biomarker. Chen L; Li Y; Deng X Medicine (Baltimore); 2023 Mar; 102(11):e33242. PubMed ID: 36930112 [TBL] [Abstract][Full Text] [Related]
2. Pan-cancer and single-cell analysis reveal dual roles of lymphocyte activation gene-3 (LAG3) in cancer immunity and prognosis. Wang Y; Zhao Y; Zhang G; Lin Y; Fan C; Wei H; Chen S; Guan L; Liu K; Yu S; Fu L; Zhang J; Yuan Y; He J; Cai H Sci Rep; 2024 Oct; 14(1):24203. PubMed ID: 39406840 [TBL] [Abstract][Full Text] [Related]
3. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures. Zhang X; Wang Y; A G; Qu C; Chen J Front Immunol; 2021; 12():721030. PubMed ID: 34531868 [TBL] [Abstract][Full Text] [Related]
4. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers. Wang N; Zhu L; Wang L; Shen Z; Huang X Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736 [TBL] [Abstract][Full Text] [Related]
5. A pan-cancer analysis of the role of Ding G; Ma T; Zhang K; Chen G; Shen J; Zhang S; Li K; Zhao C; Wang F; Sun J; Wang J Biotechnol Genet Eng Rev; 2024 Nov; 40(3):1456-1471. PubMed ID: 36971139 [TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of zinc and ring finger 3 in prognostic value and pan-cancer immunity. Liu M; Zhao H; Peng S; Wu Y; Liu Y; Sun W; Zen K; Sun X FASEB J; 2024 Mar; 38(5):e23523. PubMed ID: 38457275 [TBL] [Abstract][Full Text] [Related]
7. CCND1 as a Prognostic and Diagnostic Biomarker and the Impact of Its Epigenetic Alterations on Cancer Survival. Taha MY; Mohamed NO; Alhaj LG; Altayeb I; Basheer A; Idrees S; Said AM; Alfaki M Cureus; 2024 Jul; 16(7):e65504. PubMed ID: 39188436 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint. Bai KH; Zhang YY; Li XP; Tian XP; Pan MM; Wang DW; Dai YJ Comput Struct Biotechnol J; 2022; 20():5226-5234. PubMed ID: 36187930 [TBL] [Abstract][Full Text] [Related]
9. Pan-Cancer Analysis Revealed Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J J Oncol; 2022; 2022():3477148. PubMed ID: 35069733 [TBL] [Abstract][Full Text] [Related]
10. The molecular feature of macrophages in tumor immune microenvironment of glioma patients. Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502 [TBL] [Abstract][Full Text] [Related]
11. Violations of proportional hazard assumption in Cox regression model of transcriptomic data in TCGA pan-cancer cohorts. Zeng Z; Gao Y; Li J; Zhang G; Sun S; Wu Q; Gong Y; Xie C Comput Struct Biotechnol J; 2022; 20():496-507. PubMed ID: 35070171 [TBL] [Abstract][Full Text] [Related]
12. A comprehensive pan-cancer analysis of the expression characteristics, prognostic value, and immune characteristics of Fei L; Lu Z; Xu Y; Hou G Front Genet; 2022; 13():920897. PubMed ID: 36035140 [No Abstract] [Full Text] [Related]
13. Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA. Ye B; Shi J; Kang H; Oyebamiji O; Hill D; Yu H; Ness S; Ye F; Ping J; He J; Edwards J; Zhao YY; Guo Y RNA Biol; 2020 Nov; 17(11):1666-1673. PubMed ID: 31607216 [TBL] [Abstract][Full Text] [Related]
14. A Systematic Pan-Cancer Analysis of YY1 Aberrations and their Relationship with Clinical Outcome, Tumor Microenvironment, and Therapeutic Targets. Fu X; Ji F; He Q; Qiu X J Immunol Res; 2022; 2022():5826741. PubMed ID: 35791393 [TBL] [Abstract][Full Text] [Related]
15. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy. Zhang J; Wang K; Hainisayimu T; Li H Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686 [TBL] [Abstract][Full Text] [Related]
16. Stromal Interaction Molecule 1 (STIM1) is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Solid Tumors. Zhang Z; Wang Z; Liu Y; Zhao L; Fu W J Environ Pathol Toxicol Oncol; 2023; 42(2):11-30. PubMed ID: 36749087 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value of Zhang Y; Wu D; Yu T; Liu Y; Zhao C; Xue R Heliyon; 2024 Oct; 10(19):e38308. PubMed ID: 39397950 [TBL] [Abstract][Full Text] [Related]
18. Integrative omics analysis reveals relationships of genes with synthetic lethal interactions through a pan-cancer analysis. Guo L; Li S; Qian B; Wang Y; Duan R; Jiang W; Kang Y; Dou Y; Yang G; Shen L; Wang J; Liang T Comput Struct Biotechnol J; 2020; 18():3243-3254. PubMed ID: 33240468 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value and immunological role of PTPN21 in pan-cancer analysis. Yang Y; Yang W; Su X; Cheng C Cent Eur J Immunol; 2023; 48(2):111-125. PubMed ID: 37692032 [TBL] [Abstract][Full Text] [Related]
20. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types. Guo B; Wang Y; Liu W; Zhang S Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]